AbCellera Biologics (ABCL) Liabilities and Shareholders Equity (2020 - 2026)

AbCellera Biologics has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $1.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 2.76% year-over-year to $1.3 billion; the trailing twelve-month figure through Mar 2026 stood at $5.4 billion (down 1.6% YoY), and the FY2025 full-year result was $1.4 billion, changed 0.26% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $1.3 billion, down from $1.4 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $1.6 billion in Q2 2022, with the low at $1.3 billion in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $1.5 billion across 5 years, with a median of $1.5 billion in 2024.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity surged 41.09% — and 2024, when it decreased 8.57%.
• AbCellera Biologics' Liabilities and Shareholders Equity stood at $1.5 billion in 2022, then fell by 3.43% to $1.5 billion in 2023, then declined by 8.57% to $1.4 billion in 2024, then decreased by 0.26% to $1.4 billion in 2025, then slipped by 3.67% to $1.3 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.3 billion (Q1 2026), $1.4 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.